Clinical Trials
174 trialsAnalyzing a New Mechanism in Response to Tamoxifen Therapy in Breast Cancer Patients
Roswell Park Cancer Institute
PHACS
Institut Claudius Regaud
OXYTAM
Institut Claudius Regaud
MIRHO
Institut Claudius Regaud
Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer
Canadian Cancer Trials Group
EMPRESS
MedSIR
MNEMOSYNE
Centre Oscar Lambret
Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer
City of Hope Medical Center
Umbrella Trial of Subtype-Targeted Therapies in ER+/HER2- Breast Cancer
Stanford University
SOFT
ETOP IBCSG Partners Foundation
TEXT
ETOP IBCSG Partners Foundation
Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer
Big Ten Cancer Research Consortium
Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer
National Cancer Institute (NCI)
MORPHEUS HR+BC
Hoffmann-La Roche
Effect of Metformin on Endometrial Thickness in Postmenopausal Breast Cancer Patients Receiving Tamoxifen
Uruk University
METALLICA
MedSIR
Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer
National Cancer Institute (NCI)
T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer
University of California, San Francisco
Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer
Dana-Farber Cancer Institute
Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer
Medical College of Wisconsin
Endocrine Response in Women With Invasive Lobular Breast Cancer
University of Pittsburgh
KARISMA2
Karolinska Institutet
ASPIRE
Emory University
Letrozole or Tamoxifen Citrate in Treating Older Postmenopausal Women Undergoing Surgery for Breast Cancer
Institut du Cancer de Montpellier - Val d'Aurelle
Karisma-1
Karolinska Institutet
Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast
Northwestern University
IBIS-1
Queen Mary University of London
PADMA
GBG Forschungs GmbH
Treatment of Metastatic Breast Cancer With Fulvestrant Plus Palbociclib or Tamoxifen Plus Palbociclib
University of Pittsburgh
IBIS-II DCIS
Queen Mary University of London
Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer
GOG Foundation
The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast Cancer
Johns Hopkins University
HORMONET
AC Camargo Cancer Center
TP-II
Palleos Healthcare GmbH
Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid
Austrian Breast & Colorectal Cancer Study Group
MONALEESA-7
Novartis
LAPATAM
European Organisation for Research and Treatment of Cancer - EORTC
Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II/III Breast Cancer (Women)
University of Nebraska
Tamoxifen-RAD001 Versus Tamoxifen Alone in Patients With Anti-aromatase Resistant Breast Metastatic Cancer
ARCAGY/ GINECO GROUP
REGOVAR
ARCAGY/ GINECO GROUP
Randomized Study Comparing CMF and Goserelin + Tamoxifen in Premenopausal Receptor-positive Patients
Austrian Breast & Colorectal Cancer Study Group
Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer
Eastern Cooperative Oncology Group
Combination Chemotherapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Has Spread to the Lymph Nodes
Eastern Cooperative Oncology Group
A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer
Novartis
Efficacy and Toxicity of Bicalutamide and Dutasteride vs. Standard Care for Prostate Cytoreduction for Brachytherapy
CHU de Quebec-Universite Laval
MINDACT
European Organisation for Research and Treatment of Cancer - EORTC
Poseidon
The Netherlands Cancer Institute
REaCT-RETT
Ottawa Hospital Research Institute
Radiation Therapy With or Without Optional Tamoxifen in Treating Women With Ductal Carcinoma in Situ
Radiation Therapy Oncology Group
A Study of Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Metastatic Breast Cancer
University of California, San Francisco